Johnson & Johnson’s Spravato, a nasal spray for depression and potential blockbuster medicine, won recommendation for approval from a European Medicines Agency panel.
Pear Therapeutics announced the filing of a submission to the U.S. Food and Drug Administration seeking marketing authorization for Somryst, a prescription digital therapeutic (PDT) intended for use in the treatment of adults with chronic insomnia and depression.
Flow, a medical device company, launched a medication-free treatment for depression comprising a brain stimulation headset and therapy app.
Allergan Plc’s Vraylar won U.S. regulatory approval to treat depressive episodes of bipolar I disorder, expanding the scope of treatment to a full spectrum of symptoms related to the condition.
When major depressive disorder does not respond to at least two different types of antidepressant treatments in a moderate-to-severe depressive episode, it’s reclassified as treatment-resistant depression (TRD). South San Francisco-based VistaGen Therapeutics’ AV-101 failed to meet the primary efficacy endpoints for TRD in a Phase II clinical trial.
While nine out of 10 phone apps for depression and smoking cessation assessed in a recent study were found to be sharing user data with third parties, only two out of three disclosed they were doing so.
A recent study showed that ketamine can possibly provide hours of relief for depression patients.
Sage Therapeutics shares were up after the company won approval for the postpartum depression treatment Zulresso (brexanalone).
Aptar Pharma’s Bidose Nasal Drug Delivery Device Approved by U.S. FDA for Breakthrough Treatment of Depression
Aptar Pharma, a leading drug delivery systems provider, announced that the company’s Bidose nasal spray device was approved by the U.S. FDA for a breakthrough therapy in the field of depression.
Researchers at Indiana University developed a blood test that could help more accurately diagnose post-traumatic stress disorder.